The latest price target for Bausch Health Companies (NYSE:BHC) was reported by Jefferies on February 6, 2025. The analyst firm set a price target for $8.00 expecting BHC to rise to within 12 months (a possible 11.89% upside). 10 analyst firms have reported ratings in the last year.

The latest analyst rating for Bausch Health Companies (NYSE:BHC) was provided by Jefferies, and Bausch Health Companies downgraded their hold rating.

The last upgrade for Bausch Health Companies Inc happened on September 20, 2023 when Jefferies raised their price target to $16. Jefferies previously had a hold for Bausch Health Companies Inc.

The last downgrade for Bausch Health Companies Inc happened on February 6, 2025 when Jefferies changed their price target from $12 to $8 for Bausch Health Companies Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bausch Health Companies, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bausch Health Companies was filed on February 6, 2025 so you should expect the next rating to be made available sometime around February 6, 2026.

While ratings are subjective and will change, the latest Bausch Health Companies (BHC) rating was a downgraded with a price target of $12.00 to $8.00. The current price Bausch Health Companies (BHC) is trading at is $7.15, which is out of the analyst’s predicted range.